Skip to main content
Ipsen Home Page
Press shift tab to select search category
Loading...
  • Newsroom arrow down
      < Back
    • Newsroom
    • Press Releases
    • Media Updates
    • Media Resources
    • Media Contacts
    • Subscribe
  • Investors arrow down
      < Back
    • Investors
    • Investors
    • Financial Results
    • Annual Reports & Regulated Information
    • Investor Events & Financial Calendar
    • Shareholder Information
    • Subscribe
    • Ratings & Bonds
  • Careers arrow down
      < Back
    • Careers
    • Careers
    • Working at Ipsen
    • Culture
    • Job Search
  • Contacts arrow down
      < Back
    • Contacts
    • Contacts
    • Our Locations
    • Report Side Effects
    • Subscribe
  • Press shift tab to select search category
    Loading...
  •         EN  arrow_down
    • English EN
    • Français FR
  •  Global
    <
    • Global EN FR
    • Annual Report EN FR
    • Americas
    • Asia Pacific
    • Europe
    • Middle East & Africa
    • United States
    • Brazil
    • Canada
    • Mexico
    • Australia
    • China
    • Singapore
    • South Korea
    • Japan
    • Belgium
    • Ukraine
    • UK
    • Germany
    • France
    • Nordics
    • Greece
    • Italy
    • Netherlands
    • Spain
    • Poland
    • Russia
    • Czech Republic
    • Switzerland
    • Austria
    • UAE & Gulf
    • Saudi Arabia
  • Home
  • Company
      < Back
    • Company
    • Company
    • Leadership
    • History
    • Fondation Ipsen
  • Expertise
      < Back
    • Expertise
    • Oncology
    • Rare Disease
    • Neuroscience
    • Medicines
  • Science
      < Back
    • Science
    • Science
        < Back
      • Science
      • Oncology
      • Rare Disease
      • Neuroscience
    • Profiles
    • Partnering
        < Back
      • Partnering
      • Therapeutic focus
      • Meet the team
    • Clinical Trials
        < Back
      • Clinical Trials
      • Lay Summaries
      • Find Clinical Trials
    • Pipeline
  • Sustainability
      < Back
    • Sustainability
    • Sustainability
    • Environment
    • Patients
    • People
    • Governance
    • Our Standards
  • Patients
      < Back
    • Patients
    • Patients
    • Together for Oncology
    • Together for Rare Disease
    • Together for Neuroscience
    • Collaborate with us
  • Stories
  1. Home
  2. Press Releases
  3. Regulated Information press releases

IPSEN: Monthly information relative to the total number of voting rights and shares composing the share capital

Post navigation

Previous
Next

IPSEN: Monthly information relative to the total number of voting rights and shares composing the share capital

Monthly information relative to the total number of voting rights
and shares composing the share capital

IPSEN: Monthly information relative to the total number of voting rights and shares composing the share capital

- 10 February 2023 - 1 mins read

Monthly information relative to the total number of voting rights
and shares composing the share capital

Post navigation

Previous
Next
Share this on social media
  • Share on LinkedIn
  • Share on Facebook
  • Share on Email

Related Press Releases

18 May 2026

Ipsen – April 2026- Monthly information relative to the total...
18 May 2026

Ipsen initiates a new share buy-back program
13 May 2026

Ipsen S.A. – Evolution of the composition of the Board...
13 May 2026

Annual General Meeting of Ipsen S.A. held on 13 May...
22 April 2026

Ojemda® approved in the European Union as the first targeted...
03 April 2026

Ipsen announces that Beech Tree has obtained an exemption from...
01 April 2026

Ipsen announces the availability of its 2025 Universal Registration Document
13 March 2026

Ipsen – February 2026 – Monthly information relative to the...
12 March 2026

Ipsen appoints Michelle C. Werner as EVP, President of North...
19 February 2026

Ipsen S.A. publishes its 2025 Consolidated Financial Statements

IPN price

€157.60

 €2.70 (1.74%)

  • Media Resources
  • Annual Report
  • Contacts
  • Our Locations
Ipsen logo
LinkedIn Instagram Facebook Youtube
  • Terms and Conditions
  • Cookie Policy
  • Global Privacy Policy

© Ipsen Pharma. All rights reserved - 2026

You are now leaving the Ipsen group global website. To continue, please click on Continue?

Continue
We value your feedback

How easy was it to navigate Ipsen website and locate the information you were seeking?